SIRT3 and diabetic cardiomyopathy: Apelin, an endogenous peptide ligand of the human G-protein-coupled apelin receptor, gene therapy can correct microvascular insufficiency, cardiac hypertrophy, and heart dysfunction in diabetic cardiomyopathy by endorsing SIRT3 expression [247].